BACKGROUND: The incidence of thyroid cancer has doubled over the past decade. The
reason for this dramatic increase in incidence is controversial. Some investigators have …

Objective To correlate the presence of BRAF V600E mutation with clinicopathological
parameters. Study Design Case-control study. Setting BRAF mutation represents the most …

Background: The BRAF mutation has been shown to be associated with aggressive
clinicopathologic characteristics of papillary thyroid cancer (PTC). However, several studies …

Context: Because very few studies have examined the correlation between BRAF mutations
and clinicopathological features of papillary thyroid carcinoma (PTC), we analyzed here a …

Context: Use of BRAF mutation in papillary thyroid cancer (PTC) has the potential to improve
risk stratification of this cancer. Objective: The objective of the study was to investigate the …

Objective: To examine the prevalence of BRAF mutation among thyroid cancer histologic
subtypes and determine the association of BRAF mutation with indicators of poor prognosis …

Objective Papillary thyroid carcinoma (PTC) accounts for 95% of all thyroid carcinomas. PTC
is an epithelial tumor characterized by the proliferation of follicular cells with distinctive …

Purpose To investigate the prognostic value of BRAF V600E mutation for the recurrence of
papillary thyroid cancer (PTC). Patients and Methods This was a retrospective multicenter …

Background Papillary thyroid carcinoma is the most common endocrine malignancy and one
of the most common cancers worldwide. However, the optimal timing and frequency of …

Previous meta-analyses indicated that the BRAF V600E mutation was associated with an
increased recurrence rate of papillary thyroid carcinoma (PTC). However, with recent …